The earnings call presented a mixed picture. On one hand, there is significant progress with the completion of a pivotal study for the B-Series system and ongoing commercial traction with the S-Series OCT. However, these positive developments are counterbalanced by increased net losses and limited revenue generation, creating a cautiously optimistic outlook.
Company Guidance
During the Q3 2024 earnings call for Perimeter Medical Imaging AI, the company provided updated financial metrics and outlined its strategic guidance. For the quarter ending September 30, 2024, the company reported revenue of approximately $208,000, primarily from consumable sales and system leases, while operating expenses were $4.5 million, unchanged from the previous year. Perimeter's net loss for the quarter was around $4.6 million, or $0.07 per share, a significant increase from the $345,000 loss in the same period of 2023. The increase in net loss was attributed to noncash expenses, including the revaluation of the warrant liability and net foreign exchange loss. The company had cash and cash equivalents of $9.5 million, excluding $1.5 million in proceeds from a private placement and a $1.9 million grant receivable from the Cancer Prevention and Research Institute of Texas. The company is advancing its B-Series OCT with ImgAssist AI, having completed enrollment in a pivotal trial involving approximately 530 women across 10 U.S. sites. The trial aims to assess the device's effectiveness in breast-conserving surgeries, with results anticipated to support an FDA submission in 2025. Perimeter highlighted the significance of the B-Series' AI technology, which could broaden its user base among 8,000 breast surgeons in the U.S., emphasizing its potential to reduce the learning curve and aid in margin assessment during surgeries.
Completion of Patient Enrollment in Pivotal Study
Perimeter announced the completion of patient enrollment for a pivotal study evaluating the B-Series system in breast surgeries. Approximately 530 women were enrolled, with results expected to support a 2025 FDA submission.
S-Series OCT Commercial Traction
Perimeter has placed 14 S-Series OCT devices in commercial use in the U.S., showing positive commercial traction and creating a network of early adopters.
Anticipated FDA Submission and Commercial Launch
If the B-Series trial is successful, Perimeter plans to submit for FDA authorization in early 2025, which would allow for the full commercial launch of the B-Series OCT with ImgAssist AI.
---
Perimeter Medical Imaging AI (TSE:PINK) Earnings, Revenues Date & History
The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
TSE:PINK Earnings-Related Price Changes
Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 14, 2024
C$0.46
C$0.50
+8.70%
Aug 14, 2024
C$0.36
C$0.36
0.00%
May 14, 2024
C$0.58
C$0.57
-1.72%
Mar 28, 2024
C$0.87
C$0.87
0.00%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Perimeter Medical Imaging Ai Inc (TSE:PINK) report earnings?
Perimeter Medical Imaging Ai Inc (TSE:PINK) is schdueled to report earning on Apr 25, 2025, TBA Not Confirmed.
What is Perimeter Medical Imaging Ai Inc (TSE:PINK) earnings time?
Perimeter Medical Imaging Ai Inc (TSE:PINK) earnings time is at Apr 25, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.